



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/34	A1	(11) International Publication Number: WO 97/27176 (43) International Publication Date: 31 July 1997 (31.07.97)
(21) International Application Number: PCT/GB97/00185 (22) International Filing Date: 22 January 1997 (22.01.97) (30) Priority Data: 9601228.1 22 January 1996 (22.01.96) GB PCT/GB97/00156 20 January 1997 (20.01.97) WO (34) Countries for which the regional or international application was filed: AT et al. (71) Applicant: MEDEVA EUROPE LIMITED [GB/GB]; 10 St. James's Street, London SW1A 1EF (GB). (72) Inventors: HARRIS, Michael, Christopher, James; Chiro-science Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). ZAVAREH, Hooshang, Shahriari; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: OPTICAL RESOLUTION OF METHYLPHENIDATE BY 0,0'-BISAROYL TARTARIC ACIDS (57) Abstract Single isomer methylphenidate, selected from the <i>d</i> - and <i>l</i> -threo-enantiomers, has been obtained in purified form, to the extent of less than 2 % by weight of a contaminant selected from resolving agent and ritalinic acid. This is achieved by resolution of a mixture of enantiomers using an 0,0'-diaroyltartaric acid as resolving agent.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

OPTICAL RESOLUTION OF METHYLPHENIDATE BY O,O'-BISAROYL TARTARIC ACIDS

Field of the Invention

This invention relates to the resolution of *threo* methylphenidate via
5 crystallisation of diastereomeric salts, and to the especially pure enantiomers thus obtained.

Background of the Invention

Methylphenidate is a therapeutic agent that is widely used in the treatment of
attention-deficient hyperactivity disorder. It is a controlled substance.

10 Methylphenidate was first prepared as a mixture of the *erythro* and *threo*
racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which
revealed that the therapeutic activity resides in the *threo* diastereomer. It is now
considered that it is the *d-threo* [or (*R,R*)] enantiomer that has the preferred
therapeutic activity. Uses of this enantiomer are disclosed in PCT/GB96/01688,
15 PCT/GB96/01689 and PCT/GB96/01690, the contents of which are incorporated
herein by reference.

The resolution of *threo* methylphenidate can be achieved using the expensive
resolving agent 1,1'-binaphthyl-2,2'-diyl hydrogen phosphate, a process first
reported by Patrick *et al* (The Journal of Pharmacology and Experimental
20 Therapeutics, 241:152-158 (1987)), and subsequently used by other workers in the
field (e.g. Aoyama *et al*, Journal of Chromatography, 494:420 (1989)). This is
perceived to be a more efficient procedure than the method disclosed in US-A-
2957880, wherein the corresponding amide of *erythro* methylphenidate (i.e. R-
CONR₂ rather than R-CON₂Me) is resolved with tartaric acid prior to amide
25 hydrolysis and equilibration at the benzylic centre, followed by esterification of the
resultant *threo*-acid.

Summary of the Invention

This invention is based upon the discovery that racemic *threo* methylphenidate
can be resolved using inexpensive carboxylic acids, specifically O,O'-diaroyltartaric
30 acids, with surprising efficiency. In one embodiment of the present invention, either
D- or L-O,O-di-toluoyltartaric acid forms diastereomeric salts with *threo*-
methylphenidate, and these salts are very readily separated.

An important consequence of this discovery is that the desired enantiomer is obtained in greater chemical purity than by any prior method. Thus, while the process of Patrick *et al* may give the desired product contaminated with resolving agent, this contaminant can only be removed by repeated extractions that cause
5 hydrolysis of the ester, leaving ritalinic acid as a contaminant.

Needless to say, a product intended for administration to humans should be as pure as possible. Surprisingly, the process of this invention gives the desired enantiomer in very high chemical and enantiomeric purity. In particular, the product is substantially free of resolving agent and/or ritalinic acid (and/or the opposite
10 enantiomer). This purity can be at least 98%, preferably at least 99%, more preferably at least 99.5%, and most preferably at least 99.9%. The product may be in free base form or as a pharmaceutically-acceptable salt, e.g. the hydrochloride.

Description of the Invention

The process of this invention may be carried out under conditions that are
15 generally known to those skilled in the art of classical salt resolution procedures. For example, a mixture of *threo*-methylphenidate and 1 molar equivalent of D-*O*, *O*-ditoluoyltartaric acid in an inert organic solvent is heated and then allowed to cool; the resultant precipitate is filtered, washed with an appropriate solvent and dried to afford directly a salt enriched in at least 97% ee *d-threo*-methylphenidate, i.e.
20 containing less than 1.5% of the opposite enantiomer. Enrichment to higher ee, e.g. at least 99%, can be simply achieved, by reslurrying in fresh solvent and filtering. This is a great improvement on the literature method using 1,1'-binaphthyl-2,2'-diyl hydrogen phosphate, described by Patrick *et al*, *supra*, in which the first crystallisation gave a salt corresponding to 85-90% ee material, and further
25 recrystallisation of this material was necessary to raise the ee to 95-97%. The latter level of optical purity is achieved in the present invention in one crystallisation, with an overall higher yield. The method of this invention is therefore more efficient and more economical than the method described by Patrick *et al*.

Methylphenidate may initially be obtained as a salt of the resolving agent.
30 This may be converted directly to the hydrochloride salt, or any other pharmaceutically-acceptable salt, by a salt exchange procedure. It may be preferable

to release the free base, by salt cracking. If desired, the free base can then be converted to a salt form. All these procedures are known to those skilled in the art.

Further advantages of the present invention are as follows:

- 5 (i) Salt cracking at pH 9-10 is by addition of aqueous sodium hydroxide, whereas dilute aqueous sodium carbonate is needed for salts of the more base-labile 1,1'-binaphthyl-2,2'-diyl hydrogen phosphate; this renders the novel process more volume efficient.
- (ii) Lower volume of aqueous medium in (i) means fewer extractions into organic solvent (TBME rather than diethyl ether) to isolate methylphenidate free base.
- 10 (iii) Chemical robustness of DTTA allows for clean and efficient recovery.

Either isomer of methylphenidate can be easily obtained by this procedure, e.g. by simply using the D- or L-isomer of the diaroyl tartaric acid derivative as required.

15 Single isomer methylphenidate according to this invention, especially pure *d*-*threo*-methylphenidate, can be used in therapy for the same purposes as the racemate, e.g. in the treatment of ADHD or narcolepsy. The compound can be formulated with any suitable carrier, in any suitable dosage, as will be apparent to one of ordinary skill in the art. Reference in this context may be made to any of the three PCT Applications identified above.

20 The following Example illustrates the invention.

Example

Ditoluoyl-D-tartaric acid (5.033 g, 12.4 mmol) was suspended in a solution of 2% methanol in acetone (10 ml), and a solution of *threo*-methylphenidate (2.9 g, 12.4 mmol) in the same solvent (10 ml) was added. The solution was gently warmed to reflux whereupon all the reagents dissolved. The solution was immediately cooled and crystals began to form. The solution was allowed to stand at 4°C for 17 hours and was then filtered. The crystals were washed with acetone (3 x 15 ml) and dried *in vacuo* to yield the ditoluoyl-D-tartrate salt of *d*-*threo* methylphenidate (3.516 g, 44.3% by weight; corresponding to 97% ee *d*-*threo* methylphenidate, as determined by chiral HPLC after salt cracking). The mother

liquors were dried *in vacuo* to yield the ditoluoyl-D-tartrate salt of *l-threo*-methylphenidate as a solid, dry form (4.508 g, 50.5% yield, 88% ee).

The ditoluoyl-D-tartrate salt of *d-threo*-methylphenidate (3.486 g), obtained as described above, was suspended in 2% methanol in acetone, and warmed to c.
5 40°C and cooled. This did not dissolve the solid which was stirred at room temperature for 24 hours. The suspension was filtered, the solid washed with acetone (10 ml) and dried *in vacuo*, to yield diastereomerically pure material (3.209 g, 92% recovery, corresponding to >99% ee *d-threo*-methylphenidate).

Repeating this protocol using isopropanol: methanol as the solvent,
10 gave the same salt, on initial crystallisation, enriched in at least 98%. Reslurrying increased this.

For the purposes of comparison, USP grade *dl-threo*-methylphenidate hydrochloride (3.36 g) was dissolved in an aqueous solution of sodium carbonate (45 ml, 2% w/v), and the clear solution was extracted with diethyl ether (3 x 50 ml).
15 The combined ethereal layers were dried (MgSO₄), filtered, and evaporated to dryness. The resulting pale yellow oil together with (R)-(-)-1,1'-binaphthyl-2,2'-diyl hydrogen phosphate (3.36 g) were dissolved in a hot mixture of acetone/methanol (95:5). The solution was gently stirred and cooled to 5°C and maintained for 12 hours. The resulting white crystals (2.98 g) were isolated by filtration and
20 recrystallised from acetone/methanol (98:2). This product was then treated with a 2% aqueous solution of sodium carbonate and extracted with diethyl ether (4 x 50 ml). The combined ethereal layers were dried (MgSO₄) and filtered. An excess saturated solution of hydrogen chloride in ether was then added and the resulting hydrochloride salt was filtered, rinsed with ether, and recrystallised from
25 methanol/ether. The resulting white crystalline product was analysed by HPLC and proton NMR:

% w/w *l-threo*:3.7%

e.e.:92.6%

ritalinic acid:trace amount but not quantified by HPLC or NMR

30 resolving agent:approximately 4% by NMR

CLAIMS

1. Single isomer methylphenidate, selected from the *d*- and *l*-*threo*-enantiomers, or a pharmaceutically-acceptable salt thereof, in combination with less than 2% by weight of a contaminant selected from resolving agent and ritalinic acid.
- 5 2. Methylphenidate according to claim 1, in combination with less than 1% by weight of the contaminant.
3. Methylphenidate according to claim 1, in combination with less than 0.5% by weight of the contaminant.
4. Methylphenidate according to claim 1, in combination with less than 0.1%
10 by weight of the contaminant.
5. Single isomer methylphenidate, selected from the *d*- and *l*-*threo*-enantiomers, or a pharmaceutically-acceptable salt thereof, which is at least 98% pure.
6. Methylphenidate according to claim 4, which is at least 99% pure.
7. Methylphenidate according to claim 4, which is at least 99.5% pure.
- 15 8. Methylphenidate according to claim 4, which is at least 99.9% pure.
9. Methylphenidate according to any preceding claim, as the free base.
10. Methylphenidate according to any of claims 1 to 8, as the hydrochloride.
11. A pharmaceutical composition comprising *d*-*threo*-methylphenidate according to any preceding claim, and a pharmaceutically-acceptable diluent or carrier.
- 20 12. Use of *d*-*threo*-methylphenidate according to any of claims 1 to 10, for the manufacture of a medicament for use in the treatment of a condition susceptible to treatment with methylphenidate.
13. Use according to claim 12, wherein the condition is attention-deficient hyperactivity disorder or narcolepsy.
- 25 14. A process for preparing substantially single enantiomer *d*- or *l*-*threo*-methylphenidate, which comprises resolution of a mixture of enantiomers using an *O,O'*-diaroyltartaric acid as resolving agent.
15. A process according to claim 14, wherein the resolving agent is D- or L-*O,O'*-ditoluoyltartaric acid.
- 30 16. A process according to claim 14 or claim 15, which additionally comprises salt cracking using aqueous alkali metal hydroxide.

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No
PCT/GB 97/00185

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 957 880 A (R. ROMETSCH) 25 October 1960 cited in the application see the whole document see column 6, line 11 - line 29 ---	1-13
X	J. MED. CHEM. (1996), 39(6), 1201-9 CODEN: JMCMAR; ISSN: 0022-2623, 1996, XP000602079 DEUTSCH, HOWARD M. ET AL: "Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs" see the whole document scheme 1, table 1 --- -/-	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

4 March 1997

Date of mailing of the international search report

12.03.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Kissler, B

INTERNATIONAL SEARCH REPORT

Inten. .nal Application No

PCT/GB 97/00185

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. PHARMACOL. EXP. THER. (1987), 241(1), 152-8 CODEN: JPETAB;ISSN: 0022-3565, 1987, XP000602457 PATRICK, KENNERLY S. ET AL: "Pharmacology of the enantiomers of threo-methylphenidate" cited in the application see the whole document ---	1-13
Y	WO 95 31436 A (MERRELL DOW PHARMA ;NAKAMURA MITSUO (JP); SHIGA MASATOSHI (JP)) 23 November 1995 scheme B, page 4 ---	14-16
X	J. PHARM. SCI. (1967), 56(12), 1689-90 CODEN: JPMSAE, 1967, XP000602090 SHAFI'EE, ABBAS ET AL: "Absolute configurations of enantiomeric pheniramines, methylphenidates, and pipradrols" see the whole document ---	1-13
Y	PATENT ABSTRACTS OF JAPAN vol. 95, no. 009 & JP 07 247286 A (SANKYO CO LTD), 26 September 1995, see abstract ---	14-16
X	J. LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. XXXIV, no. 10, 1994, pages 989-997, XP000602493 see the whole document -----	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/00185

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2957880 A	25-10-60	NONE	
WO 9531436 A	23-11-95	AU 2284095 A	05-12-95
		CA 2189000 A	23-11-95
		ZA 9503793 A	19-01-96